Unecritinib also displayed notable growth inhibitory effects on several cancer cell lines carrying ALK rearrangements or mutations or overexpressing c-MET, with an IC50 of 180 to 378.9 nm for lung cancer cells and an IC50 of 23.5 nm for gastric cancer cells overexpressing c-MET. This evidence concerns the gene ALK and lung carcinoma.